Couple shots on goal here in the near term, mainly accelerating revenue based off existing sales of PCR based COVID tests plus a new 12-min rapid antigen test coming in Feb. This is a turnaround play as the stock was previously priced for bankruptcy. Valuation should be 10-12x sales or $25-$30. Patience on this one, its a slow grinder.
Company has been plagued by system issues, dilutive financing, short sightedness and questionable management; all of which are great reasons to say the bar is about as low as it can get on this one. About a year ago a small biotech hedge fund took control (DAFNA), kicked out the CEO and installed new blood. DAFNA also brought in a high caliber roster of...
